Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10288209" target="_blank" >RIV/00216208:11110/14:10288209 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/14:10288209

Result on the web

<a href="http://dx.doi.org/10.1007/s40264-014-0238-8" target="_blank" >http://dx.doi.org/10.1007/s40264-014-0238-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40264-014-0238-8" target="_blank" >10.1007/s40264-014-0238-8</a>

Result language

angličtina

Original language name

Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

Original language description

Incretin-based therapies either increase endogenous levels of glucagon-like peptide-1 by prolonging its half-life (DPP-4 inhibitors) or directly stimulate its receptor (glucagon-like peptide-1 analogues; GLP-1 RA). They are currently widely used for thetreatment of patients with type 2 diabetes mellitus owing to good antidiabetic efficacy, low risk of hypoglycemia, and relatively few other side effects. They also offer potential additional benefits such as weight neutrality or weight loss, positive effects on blood pressure and lipid levels, and potential cardio- and neuroprotectivity. Some experimental and clinical studies have raised concerns with respect to potential cardiovascular and pancreatic side effects of these therapies such as increased risk of heart failure with DPP-4 inhibitors as well as acute pancreatitis and pancreatic cancer with both classes. The available data are at present not robust enough to enable firm conclusions regarding these potential associations. Nevert

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FB - Endocrinology, diabetology, metabolism, nutrition

OECD FORD branch

—

Project

<a href="/en/project/7E12077" target="_blank" >7E12077: Safety Evaluation of Adverse Reactions in Diabetes</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Drug Safety

ISSN

0114-5916

e-ISSN

—

Volume of the periodical

37

Issue of the periodical within the volume

12

Country of publishing house

NZ - NEW ZEALAND

Number of pages

8

Pages from-to

1003-1010

UT code for WoS article

000345391800002

EID of the result in the Scopus database

—